(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 1.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Taysha Gene Therapies's revenue in 2025 is $8,098,000.On average, 4 Wall Street analysts forecast TSHA's revenue for 2025 to be $2,208,274,594, with the lowest TSHA revenue forecast at $1,718,607,776, and the highest TSHA revenue forecast at $2,673,389,873. On average, 2 Wall Street analysts forecast TSHA's revenue for 2026 to be $2,359,675,755, with the lowest TSHA revenue forecast at $2,209,638,569, and the highest TSHA revenue forecast at $2,509,712,942.
In 2027, TSHA is forecast to generate $2,231,462,159 in revenue, with the lowest revenue forecast at $2,231,462,159 and the highest revenue forecast at $2,231,462,159.